Broome Oncology
Latest Clinical News

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma (04-16-2019)

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy,... Continue Reading

Most women can get mammograms every other year starting at age 50 (04-11-2019)

Women who are not at high risk for breast cancer can wait to start getting mammograms until age 50 and be screened every other year, according to new guidelines from the American College of Physicians. Women at high risk for breast cancer are those with... Continue Reading

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer (04-8-2019)

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in... Continue Reading

CD40 Combination Therapy Can Shrink Pancreatic Tumors (04-4-2019)

A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients – 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this strategy... Continue Reading

GARNET Study Suggets Dostarlimab Promising for Uterine/Endometrial Cancer (03-28-2019)

An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising.  These data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu,... Continue Reading

NCCN Updates Ovarian Cancer Guidelines (03-26-2019)

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes. All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2... Continue Reading

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer (03-20-2019)

PHILADELPHIA, PA– Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While... Continue Reading

Lynparza Delays Progression of BRCA-mutated Metastatic Pancreatic Cancer (03-18-2019)

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer... Continue Reading

Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer (03-14-2019)

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT... Continue Reading

Non-Chemotherapy Combo Approved for Treatment-Naïve CLL/SLL Patients (03-11-2019)

The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) in combination with Gazyva (obinutuzumab) for treatments of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). 1 The FDA approval was based... Continue Reading

FDA Approves Lonsurf® for Treatment of Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (03-8-2019)

The United States Food and Drug Administration (FDA) has approved Lonsurf® (trifluridine/tipiracil)) as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines... Continue Reading

FDA Approves Keytruda for Adjuvant Treatment of Melanoma (03-4-2019)

On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Approval was based on EORTC1325/KEYNOTE‑054... Continue Reading

Next Page »